vs

Side-by-side financial comparison of CORE MOLDING TECHNOLOGIES INC (CMT) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

CORE MOLDING TECHNOLOGIES INC is the larger business by last-quarter revenue ($74.7M vs $60.1M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 19.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -2.2%).

Core Molding Technologies, Inc. was founded in 1988 and now based in Columbus, Ohio. The company manufactures sheet molding compounds (SMC), and molds fiberglass reinforced plastics. It occupies over 1,000,000 square feet of manufacturing space and its main subsidiaries are in Matamoros, Mexico, Gaffney, South Carolina, and Cincinnati, Ohio. In 2011, Core Molding Technologies formed Core Specialty Composites, LLC.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

CMT vs RYTM — Head-to-Head

Bigger by revenue
CMT
CMT
1.2× larger
CMT
$74.7M
$60.1M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+64.3% gap
RYTM
83.8%
19.5%
CMT
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
43.8%
-2.2%
CMT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CMT
CMT
RYTM
RYTM
Revenue
$74.7M
$60.1M
Net Profit
$-55.6M
Gross Margin
15.2%
88.1%
Operating Margin
4.8%
-87.1%
Net Margin
-92.6%
Revenue YoY
19.5%
83.8%
Net Profit YoY
EPS (diluted)
$0.35
$-0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMT
CMT
RYTM
RYTM
Q1 26
$60.1M
Q4 25
$74.7M
$57.3M
Q3 25
$58.4M
$51.3M
Q2 25
$79.2M
$48.5M
Q1 25
$61.4M
$32.7M
Q4 24
$62.5M
$41.8M
Q3 24
$73.0M
$33.3M
Q2 24
$88.7M
$29.1M
Net Profit
CMT
CMT
RYTM
RYTM
Q1 26
$-55.6M
Q4 25
$-47.5M
Q3 25
$1.9M
$-52.9M
Q2 25
$4.1M
$-46.6M
Q1 25
$2.2M
$-49.5M
Q4 24
$-43.3M
Q3 24
$3.2M
$-43.6M
Q2 24
$6.4M
$-32.3M
Gross Margin
CMT
CMT
RYTM
RYTM
Q1 26
88.1%
Q4 25
15.2%
91.6%
Q3 25
17.4%
89.3%
Q2 25
18.1%
88.6%
Q1 25
19.2%
88.8%
Q4 24
15.8%
90.9%
Q3 24
16.9%
88.5%
Q2 24
20.0%
89.9%
Operating Margin
CMT
CMT
RYTM
RYTM
Q1 26
-87.1%
Q4 25
4.8%
-82.2%
Q3 25
4.4%
-102.6%
Q2 25
6.6%
-93.4%
Q1 25
4.6%
-143.7%
Q4 24
1.4%
-98.6%
Q3 24
4.9%
-132.0%
Q2 24
8.4%
-139.2%
Net Margin
CMT
CMT
RYTM
RYTM
Q1 26
-92.6%
Q4 25
-83.0%
Q3 25
3.2%
-103.1%
Q2 25
5.1%
-96.1%
Q1 25
3.6%
-151.4%
Q4 24
-103.6%
Q3 24
4.3%
-131.2%
Q2 24
7.2%
-110.9%
EPS (diluted)
CMT
CMT
RYTM
RYTM
Q1 26
$-0.83
Q4 25
$0.35
$-0.73
Q3 25
$0.22
$-0.82
Q2 25
$0.47
$-0.75
Q1 25
$0.25
$-0.81
Q4 24
$-0.01
$-0.71
Q3 24
$0.36
$-0.73
Q2 24
$0.73
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMT
CMT
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$38.1M
$340.6M
Total DebtLower is stronger
$17.6M
Stockholders' EquityBook value
$158.2M
$122.9M
Total Assets
$228.1M
$442.3M
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMT
CMT
RYTM
RYTM
Q1 26
$340.6M
Q4 25
$38.1M
$388.9M
Q3 25
$42.4M
$416.1M
Q2 25
$43.2M
$291.0M
Q1 25
$44.5M
$314.5M
Q4 24
$41.8M
$320.6M
Q3 24
$42.3M
$298.4M
Q2 24
$37.8M
$319.1M
Total Debt
CMT
CMT
RYTM
RYTM
Q1 26
Q4 25
$17.6M
Q3 25
$18.2M
Q2 25
$18.8M
Q1 25
$19.2M
Q4 24
$19.7M
Q3 24
$20.2M
Q2 24
$20.6M
Stockholders' Equity
CMT
CMT
RYTM
RYTM
Q1 26
$122.9M
Q4 25
$158.2M
$139.1M
Q3 25
$155.4M
$148.8M
Q2 25
$153.5M
$-11.9M
Q1 25
$149.9M
$18.9M
Q4 24
$147.4M
$21.7M
Q3 24
$147.8M
$11.2M
Q2 24
$147.5M
$39.3M
Total Assets
CMT
CMT
RYTM
RYTM
Q1 26
$442.3M
Q4 25
$228.1M
$480.2M
Q3 25
$219.7M
$506.9M
Q2 25
$219.9M
$372.7M
Q1 25
$223.6M
$386.7M
Q4 24
$209.6M
$392.3M
Q3 24
$220.7M
$363.6M
Q2 24
$225.7M
$381.8M
Debt / Equity
CMT
CMT
RYTM
RYTM
Q1 26
Q4 25
0.11×
Q3 25
0.12×
Q2 25
0.12×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.14×
Q2 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMT
CMT
RYTM
RYTM
Operating Cash FlowLast quarter
$5.0M
Free Cash FlowOCF − Capex
$-2.9M
FCF MarginFCF / Revenue
-3.9%
Capex IntensityCapex / Revenue
10.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMT
CMT
RYTM
RYTM
Q1 26
Q4 25
$5.0M
$-25.4M
Q3 25
$4.6M
$-26.6M
Q2 25
$3.5M
$-23.3M
Q1 25
$6.1M
$-40.4M
Q4 24
$5.0M
$-18.8M
Q3 24
$9.2M
$-25.2M
Q2 24
$15.9M
$-29.1M
Free Cash Flow
CMT
CMT
RYTM
RYTM
Q1 26
Q4 25
$-2.9M
Q3 25
$-346.0K
Q2 25
$880.0K
Q1 25
$4.3M
Q4 24
$509.0K
Q3 24
$7.0M
Q2 24
$13.0M
FCF Margin
CMT
CMT
RYTM
RYTM
Q1 26
Q4 25
-3.9%
Q3 25
-0.6%
Q2 25
1.1%
Q1 25
7.0%
Q4 24
0.8%
Q3 24
9.6%
Q2 24
14.6%
Capex Intensity
CMT
CMT
RYTM
RYTM
Q1 26
Q4 25
10.7%
Q3 25
8.4%
Q2 25
3.3%
Q1 25
2.9%
Q4 24
7.2%
Q3 24
3.1%
Q2 24
3.3%
Cash Conversion
CMT
CMT
RYTM
RYTM
Q1 26
Q4 25
Q3 25
2.44×
Q2 25
0.86×
Q1 25
2.79×
Q4 24
Q3 24
2.92×
Q2 24
2.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons